关注
Ellina Lytvyak, MD, PhD, DABOM, FRCPC
Ellina Lytvyak, MD, PhD, DABOM, FRCPC
在 ualberta.ca 的电子邮件经过验证 - 首页
标题
引用次数
引用次数
年份
Osteoarthritis prevalence and modifiable factors: a population study
R Plotnikoff, N Karunamuni, E Lytvyak, C Penfold, D Schopflocher, ...
BMC public health 15, 1-10, 2015
2502015
Liver injury after SARS‐CoV‐2 vaccination: Features of immune‐mediated hepatitis, role of corticosteroid therapy and outcome
C Efe, AV Kulkarni, BT Beretta‐Piccoli, B Magro, A Stättermayer, ...
Hepatology 76 (6), 1576-1586, 2022
832022
Severe vitamin D deficiency is a prognostic biomarker in autoimmune hepatitis
M Ebadi, RA Bhanji, VC Mazurak, E Lytvyak, A Mason, AJ Czaja, ...
Alimentary pharmacology & therapeutics 49 (2), 173-182, 2019
732019
Extrahepatic autoimmune diseases in primary biliary cholangitis: Prevalence and significance for clinical presentation and disease outcome
C Efe, M Torgutalp, I Henriksson, F Alalkim, E Lytvyak, H Trivedi, F Eren, ...
Journal of gastroenterology and hepatology 36 (4), 936-942, 2021
512021
Validation of risk scoring systems in ursodeoxycholic acid–treated patients with primary biliary cholangitis
C Efe, K Tascilar, I Henriksson, E Lytvyak, F Alalkim, H Trivedi, F Eren, ...
Official journal of the American College of Gastroenterology| ACG 114 (7 …, 2019
482019
Liver stiffness measurement by vibration-controlled transient elastography improves outcome prediction in primary biliary cholangitis
C Corpechot, F Carrat, F Gaouar, F Chau, G Hirschfield, A Gulamhusein, ...
Journal of hepatology 77 (6), 1545-1553, 2022
472022
Evaluation of classical and novel autoantibodies for the diagnosis of Primary Biliary Cholangitis-Autoimmune Hepatitis Overlap Syndrome (PBC-AIH OS)
HH Nguyen, AA Shaheen, N Baeza, E Lytvyak, SJ Urbanski, AL Mason, ...
PloS one 13 (3), e0193960, 2018
422018
Selection of quality indicators in IBD: integrating physician and patient perspectives
A Bitton, M Vutcovici, E Lytvyak, N Kachan, B Bressler, J Jones, ...
Inflammatory Bowel Diseases 25 (2), 403-409, 2019
342019
Effects of immunosuppressive drugs on COVID‐19 severity in patients with autoimmune hepatitis
C Efe, C Lammert, K Taşçılar, R Dhanasekaran, B Ebik, ...
Liver international 42 (3), 607-614, 2022
312022
Effects of tumor necrosis factor antagonists in patients with primary sclerosing cholangitis
CRH Hedin, G Sado, N Ndegwa, E Lytvyak, A Mason, A Montano-Loza, ...
Clinical Gastroenterology and Hepatology 18 (10), 2295-2304. e2, 2020
272020
Combination antiretroviral studies for patients with primary biliary cirrhosis
E Lytvyak, AJ Montano-Loza, AL Mason
World journal of gastroenterology 22 (1), 349, 2016
272016
Trends in obesity across Canada from 2005 to 2018: a consecutive cross-sectional population-based study
E Lytvyak, S Straube, R Modi, KK Lee
Canadian Medical Association Open Access Journal 10 (2), E439-E449, 2022
262022
Risk factors and outcomes associated with recurrent autoimmune hepatitis following liver transplantation
AJ Montano-Loza, V Ronca, M Ebadi, BE Hansen, G Hirschfield, S Elwir, ...
Journal of hepatology 77 (1), 84-97, 2022
232022
Healthy Alberta Communities: Impact of a three-year community-based obesity and chronic disease prevention intervention
K Raine, R Plotnikoff, D Schopflocher, E Lytvyak, CI Nykiforuk, K Storey, ...
Obesity Research & Clinical Practice 7 (2), e106, 2013
232013
Impact on follow‐up strategies in patients with primary sclerosing cholangitis
A Bergquist, TJ Weismüller, C Levy, C Rupp, D Joshi, JS Nayagam, ...
Liver international 43 (1), 127-138, 2023
222023
Impact of a 3-year multi-centre community-based intervention on risk factors for chronic disease and obesity among free-living adults: the Healthy Alberta Communities study
E Lytvyak, DL Olstad, DP Schopflocher, RC Plotnikoff, KE Storey, ...
BMC Public Health 16, 1-15, 2016
192016
Management of inflammatory bowel disease patients with clinical care pathways reduces emergency department utilization
E Lytvyak, RT Sutton, LA Dieleman, F Peerani, RN Fedorak, KI Kroeker
Crohn's & Colitis 360 2 (4), otaa080, 2020
152020
Randomized clinical trial: Combination antiretroviral therapy with tenofovir-emtricitabine and lopinavir-ritonavir in patients with primary biliary cholangitis
E Lytvyak, I Hosamani, AJ Montano-Loza, L Saxinger, AL Mason
152020
SARS-CoV-2 vaccination and risk of severe COVID-19 outcomes in patients with autoimmune hepatitis
C Efe, K Taşçılar, A Gerussi, F Bolis, C Lammert, B Ebik, AF Stättermayer, ...
Journal of Autoimmunity 132, 102906, 2022
142022
Vedolizumab therapy in children with primary sclerosing cholangitis: data from the pediatric primary sclerosing cholangitis consortium
TJ Laborda, A Ricciuto, M Aumar, N Carman, M DiGuglielmo, LG Draijer, ...
Journal of pediatric gastroenterology and nutrition 71 (4), 459-464, 2020
132020
系统目前无法执行此操作,请稍后再试。
文章 1–20